January 3, 2017 : DCMS #326

DISASTERS AVERTED — Near Miss Case Studies

Watch Out. It’s That Time of Year Again.

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Dr. Jeffrey Mechanick Part 9, Determining Best Treatment

HOMERUN SLIDES — Great Clinical Presentation Highlights

 EMPA-REG Outcome Trial, Part 3

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #56: Incretin Physiology in Health and Disease Part 6 of 6

MOST POPULAR ARTICLES OF THE MONTH

#1 Towards a Game-Changing Type 1 Diabetes Vaccine
#2 FDA Approves First Artificial Pancreas
#3 FDA Approves 2 New Diabetes Combos

This morning I was listening to my local NPR station, and although they don’t have advertising like a regular station, they do have sponsors. One sponsor, a major vitamin and nutrition company, was making a big deal about new products and new programs for the new year. I knew that I would be hearing the same kinds of ads on every TV station for some new program to shave off the pounds and make you fit in no time.

I am not saying these are bad programs. It is just when you add in the unrealistic goals that patients put on themselves, like exercising 7 days a week, failure is bound to happen. This week our Disaster Avoided looks at what can happen when our patients set unrealistic goals.

Dave Joffe

Editor-in-chief

Yes, it’s that time of year again when your phone/email/computer is busy with patients wanting appointments and making commitments to make their New Year’s Resolutions.

Often at this time of the year, my patients come in wanting to change just about everything about what they eat, when they eat, how much they eat, and the same for being physically active. So many of these patients have told me they have tried and tried and tried and failed in the past, but now it’s the New Year and it’s going to be different.

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 9 of this Exclusive Interview, Dr. Mechanick reiterates his call for the individualization of diabetes care.

In this week’s Homerun Slides, the baseline characteristics of the randomized, placebo-controlled cardiovascular outcome trial of empagliflozin.

Potential mechanisms of incretin dysfunction in type 2 diabetes: Various potential explanations have been expounded in order to explain the reduced incretin effect in type 2 diabetes. One obvious factor to examine was the secretion of GIP and GLP-1. Regarding GIP, a number of studies have compared postprandial plasma concentrations between patients with and without diabetes. These studies have revealed increased, normal, or reduced GIP levels in patients with diabetes. Considering all studies together, there does not appear to be a general defect in GIP secretion. If anything, a slight increase in postprandial GIP levels might occur in patients with early type 2 diabetes, but clearly the differences in GIP levels would not sufficiently explain any alterations in insulin of glucose concentrations.

In part 3 of this exclusive interview, Dr. Faustman discusses how a cure based on the inexpensive BCG vaccine could permanently change type 1 treatment, and whether results could also apply to type 2.

Device automatically monitors blood glucose levels and delivers insulin when appropriate for people age 14 years and older who have type 1 diabetes.

IDegLira, LixiLan go head-to-head; FDA approves Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day.